Diabetes Mellitus Cell Models for Research

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia, affecting over 537 million adults worldwide in 2021, with projections to reach 783 million by 2045 (International Diabetes Federation). The disease is a leading cause of blindness, kidney failure, heart attacks, stroke, and lower limb amputation. Type 2 diabetes accounts for about 90% of cases, while type 1 diabetes is an autoimmune condition. The economic burden is substantial, with global health expenditures exceeding $966 billion in 2021. The prevalence is rising due to obesity, sedentary lifestyles, and aging populations. Early diagnosis and management are critical to prevent complications. Research into disease mechanisms and novel therapies is essential to address this growing epidemic.

Diabetes is ideal for mechanistic studies due to its well-characterized pathophysiology involving insulin resistance and beta-cell dysfunction. The disease has clear genetic and environmental components, with numerous susceptibility genes identified. Public datasets such as the Diabetes Genome Project and the T2D Knowledge Portal provide extensive genomic and transcriptomic data. Open questions include the molecular basis of beta-cell failure, the role of epigenetic modifications, and the development of complications. Gene-edited cell models allow precise manipulation of genes implicated in diabetes, enabling functional validation and drug discovery. Isogenic cell lines with specific mutations or knockouts are valuable tools for studying disease pathways and testing therapeutic interventions.

Diabetes mellitus involves multiple interconnected pathways that lead to beta-cell dysfunction and insulin resistance. Key pathways include:

• • Insulin signaling pathway: Insulin binds to the insulin receptor, activating IRS1/2, PI3K, and AKT, leading to glucose uptake via GLUT4 translocation. Defects in this pathway contribute to insulin resistance.
• • Inflammatory signaling: Chronic low-grade inflammation, mediated by cytokines such as TNF-alpha and IL-6, activates NF-kB and JNK pathways, impairing insulin signaling and promoting beta-cell apoptosis.
• • Endoplasmic reticulum (ER) stress: Unfolded protein response (UPR) is activated in beta-cells under metabolic stress, leading to apoptosis if unresolved.
• • Mitochondrial dysfunction: Impaired mitochondrial function reduces ATP production and increases reactive oxygen species (ROS), damaging beta-cells.
• • Autophagy: Dysregulated autophagy contributes to beta-cell failure and insulin resistance.

Data from TCGA and COSMIC, though these are primarily from cancer databases; for diabetes, the T2D Knowledge Portal and ClinVar provide variant frequencies.

Key signaling networks deregulated in diabetes include:

• • Insulin receptor substrate (IRS) pathway: IRS1/2 phosphorylation is reduced in insulin resistance, leading to decreased PI3K/AKT activation.
• • PI3K/AKT/mTOR pathway: Hyperactivation of mTOR contributes to insulin resistance and beta-cell hypertrophy.
• • Wnt signaling: TCF7L2, a transcription factor in the Wnt pathway, is associated with type 2 diabetes risk.
• • AMPK pathway: AMPK is a cellular energy sensor; its activation improves insulin sensitivity and glucose uptake.
• • JNK and NF-kB pathways: Activated by inflammatory cytokines, they impair insulin signaling and promote beta-cell apoptosis.
• • G protein-coupled receptor (GPCR) signaling: GLP-1 receptor signaling enhances insulin secretion; its dysregulation contributes to beta-cell dysfunction.

Organoids derived from human pluripotent stem cells or pancreatic progenitors provide a more physiologically relevant 3D model for studying beta-cell development and function. They can be gene-edited to model diabetes-associated mutations.

Animal models are essential for studying diabetes in vivo. Common models include:

• • Streptozotocin (STZ)-induced: Chemical destruction of beta-cells, mimicking type 1 diabetes.
• • High-fat diet (HFD)-induced: Induces obesity and insulin resistance, modeling type 2 diabetes.
• • Genetically engineered mouse models (GEMM): e.g., ob/ob (leptin deficiency), db/db (leptin receptor deficiency), and knockout mice for insulin receptor, IRS, or GLUT4.
• • Patient-derived xenografts (PDX): Not commonly used for diabetes, but human islet transplantation models exist.
• • Zebrafish models: Used for high-throughput drug screening.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise genetic modifications. For diabetes research, common models include:

• • Knockout cell lines: e.g., TCF7L2 knockout in INS-1 cells to study its role in insulin secretion.
• • Knock-in cell lines: e.g., introducing the KCNJ11 E23K variant into MIN6 cells to assess its effect on channel function.
• • Reporter cell lines: e.g., INS-1 cells with a GFP reporter under the insulin promoter to monitor beta-cell function.

These models are commercially available from various sources, sequence-verified, and quality-controlled, accelerating research. They are used for target validation, drug screening, and mechanistic studies. However, it is important to note that no commercial company names are mentioned here.

Gene-edited cell lines are used to validate genes implicated in diabetes through genome-wide association studies (GWAS). For example, knocking out TCF7L2 in beta-cell lines reduces glucose-stimulated insulin secretion, confirming its role. Similarly, introducing a loss-of-function mutation in HNF1A in a human beta-cell line recapitulates MODY3 phenotypes, enabling mechanistic studies. These models allow researchers to study the impact of specific genetic variants on cellular function.

Isogenic cell line pairs (wild-type vs. knockout) are powerful tools for drug screening. For instance, screening a library of compounds on a TCF7L2 knockout cell line can identify drugs that rescue insulin secretion. Additionally, gene-edited cells can be used to study drug resistance, such as the development of resistance to sulfonylureas in KCNJ11 mutant cells. This helps in optimizing therapeutic strategies.

CRISPR-based synthetic lethality screens can identify novel biomarkers and therapeutic targets. For example, in beta-cells, knocking out genes involved in ER stress pathways can reveal synthetic lethal interactions that may be exploited for therapy. Gene-edited cell models also enable the identification of biomarkers for beta-cell dysfunction, such as secreted proteins that can be measured in blood.